
|Articles|April 13, 2022
Daily Medication Pearl: Maralixibat (Livmarli)
Author(s)Saro Arakelians, PharmD
Maralixibat (Livmarli) is an ileal bile acid transporter inhibitor indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.
Advertisement
Medication Pearl of the Day: Maralixibat (Livmarli)
Indication: Maralixibat (Livmarli) is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.
Insight:
- Dosing:The recommended dosage is 380 mcg/kg once daily, taken 30 minutes before the first meal of the day.
- Dosage forms: Oral solution 9.5 mg of maralixibat per mL.
- Adverse events: Most common adverse reactions (≥5%) are diarrhea, abdominal pain, vomiting, fat-soluble vitamin deficiency, liver test abnormalities, gastrointestinal bleeding, and bone fractures.
- Mechanism of action: Maralixibat is a reversible inhibitor of IBAT. It decreases the reabsorption of bile acids (primarily the salt forms) from the terminal ileum.
- Manufacturer: Mirum Pharmaceuticals
Source
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
2
FDA Approves Gepotidacin for Urogenital Gonorrhea in Adult and Pediatric Patients
3
Study: Many Patients Switching Biologics Because of Perceived Lack of Efficacy Treating Asthma
4
Emerging Data from the DESTINY-Breast Trials Signal Shift in Standards of Care for HER2-Positive Breast Cancer
5

















































































































































































































